Refractory Anti-HMGCR Necrotizing Myopathy With Progressive Hypercapnic Respiratory Failure Responsive to a JAK Inhibitor.
- 1University of Pittsburgh Myositis Center Division of Rheumatology and Clinical Immunology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA pitt.edu.
- 2Johns Hopkins University School of Medicine Division of Rheumatology Johns Hopkins University School of Medicine Baltimore Maryland USA jhu.edu.
Abstract
Immune-mediated necrotizing myopathy (IMNM) associated with 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies is a rare condition often associated with statin use. It typically presents with proximal weakness and markedly elevated creatine phosphokinase (CPK) levels and is often refractory, requiring long-term immunotherapy. Respiratory involvement is uncommon but can be life-threatening. Herein, we report the case of a 73-year-old woman with long-standing anti-HMGCR antibody-positive IMNM, refractory to glucocorticoids, methotrexate, azathioprine, intravenous immunoglobulin (IVIg), rituximab, and plasma exchange (PLEX), who presented with progressive hypercapnic respiratory failure. Despite ongoing treatment with IVIg, PLEX, and high-dose glucocorticoids, the patient's respiratory function worsened, and she required mechanical ventilation (MV). The addition of tofacitinib, a Janus kinase (JAK) inhibitor, coincided with marked clinical improvement, discontinuation of MV, and successful transition to room air. The patient continued to do well on this therapy, with improvement in muscle strength until outpatient discharge. The clinical benefit of JAK inhibition has been reported in dermatomyositis, overlap myositis, and anti-MDA5-positive disease, particularly in refractory cases with pulmonary or systemic involvement-but has not been described in the setting of refractory IMNM. In our patient, who had exhausted multiple conventional therapies and PLEX, the rapid clinical improvement after JAK inhibition strongly suggests a therapeutic effect and highlights the need for future studies of JAK inhibitors in IMNM.
Related
- Impact of Schizophrenia on Outcomes Following Non-Invasive Ventilation for Acute Hypercapnic Respiratory Failure in COPD
- Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis
- Case Report: Bacteremic respiratory tularemia causing refractory ARDS requiring VV-ECMO
- Respiratory viral triggers and pediatric acute necrotizing encephalopathy: a systematic review and meta-analysis of risk, clinical phenotype, and outcomes
- Refractory rapidly progressive diffuse in-stent restenosis with left main involvement: a case report.
BibTeX
@article{huang2026refractory,
title = {{Refractory Anti-HMGCR Necrotizing Myopathy With Progressive Hypercapnic Respiratory Failure Responsive to a JAK Inhibitor.}},
author = {N Huang and T B George and L Christopher-Stine and A Nicolas and C Oddis and D P Ascherman and V M Liarski},
journal = {Case reports in rheumatology},
year = {2026},
month = oct,
doi = {10.1155/crrh/7268721},
url = {https://europepmc.org/article/MED/42898491},
note = {CC BY},
}
RIS
TY - JOUR
TI - Refractory Anti-HMGCR Necrotizing Myopathy With Progressive Hypercapnic Respiratory Failure Responsive to a JAK Inhibitor.
AU - N Huang
AU - T B George
AU - L Christopher-Stine
AU - A Nicolas
AU - C Oddis
AU - D P Ascherman
AU - V M Liarski
PY - 2026
DA - 2026/10/18
JO - Case reports in rheumatology
DO - 10.1155/crrh/7268721
UR - https://europepmc.org/article/MED/42898491
AB - Immune-mediated necrotizing myopathy (IMNM) associated with 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies is a rare condition often associated with statin use. It typically presents with proximal weakness and markedly elevated creatine phosphokinase (CPK) levels and is often refractory, requiring long-term immunotherapy. Respiratory involvement is uncommon but can be life-threatening. Herein, we report the case of a 73-year-old woman with long-standing anti-HMGCR antibody-positive IMNM, refractory to glucocorticoids, methotrexate, azathioprine, intravenous immunoglobulin (IVIg), rituximab, and plasma exchange (PLEX), who presented with progressive hypercapnic respiratory failure. Despite ongoing treatment with IVIg, PLEX, and high-dose glucocorticoids, the patient's respiratory function worsened, and she required mechanical ventilation (MV). The addition of tofacitinib, a Janus kinase (JAK) inhibitor, coincided with marked clinical improvement, discontinuation of MV, and successful transition to room air. The patient continued to do well on this therapy, with improvement in muscle strength until outpatient discharge. The clinical benefit of JAK inhibition has been reported in dermatomyositis, overlap myositis, and anti-MDA5-positive disease, particularly in refractory cases with pulmonary or systemic involvement-but has not been described in the setting of refractory IMNM. In our patient, who had exhausted multiple conventional therapies and PLEX, the rapid clinical improvement after JAK inhibition strongly suggests a therapeutic effect and highlights the need for future studies of JAK inhibitors in IMNM.
SN - 2090-6889
SN - 2090-6897
ER -